InvestorsHub Logo
Followers 3
Posts 577
Boards Moderated 0
Alias Born 08/27/2020

Re: None

Wednesday, 01/10/2024 1:23:07 PM

Wednesday, January 10, 2024 1:23:07 PM

Post# of 44263
CUBT’s Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease has a goal of being in the clinic in 2024 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.